Cellectis Gets FDA Nod For Initial-Stage Non-Hodgkin Lymphoma Study
The U.S. Food and Drug Administration (FDA) has announced clearance to Cellectis‘ CLLS Investigational New Drug (IND) application to initiate a Phase 1/2a clinical trial of UCART20x22 for patients with…